Dorzolamide

Dorzolamide

File:Dorzolamide-2D-skeletal.png
Clinical data
ATC code	S01EC03 (WHO)
Pharmacokinetic data
Protein binding	~33%
Elimination half-life	4 months
Identifiers
IUPAC name 2-ethylamino-4-methyl-5, 5-dioxo-5$l^{6}, 7-dithiabicyclo[4.3.0] nona-8,10- diene-8-sulfonamide
CAS Number	130693-82-2 120279-96-1
PubChem CID	3154
DrugBank	APRD00577
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C10H16N2O4S3
Molar mass	324.443 g/mol

Dorzolamide is a carbonic anhydrase inhibitor. It is an anti-glaucoma agent and topically applied in the form of eye drops. This drug was the first drug in human therapy (market introduction 1995) which resulted from structure-based drug design.

Trusopt (dorzolamide hydrochloride ophthalmic solution) is a carbonic anhydrase inhibitor formulated for topical ophthalmic use. Trusopt is used to lower increased intraocular pressure in open-angle glaucoma and ocular hypertension.

References

• Kubinyi H (1999). "Chance favors the prepared mind--from serendipity to rational drug design". J Recept Signal Transduct Res. 19 (1–4): 15–39. PMID 10071748.
• Plummer C, MacKay E, Gelatt K. "Comparison of the effects of topical administration of a fixed combination of dorzolamide-timolol to monotherapy with timolol or dorzolamide on IOP, pupil size, and heart rate in glaucomatous dogs". Vet Ophthalmol. 9 (4): 245–9. PMID 16771760.CS1 maint: Multiple names: authors list (link)
• Grover S, Apushkin M, Fishman G (2006). "Topical dorzolamide for the treatment of cystoid macular edema in patients with retinitis pigmentosa". Am J Ophthalmol. 141 (5): 850–8. PMID 16546110.CS1 maint: Multiple names: authors list (link)
• Almeida G, Faria e Souza S (2006). "Effect of topical dorzolamide on rabbit central corneal thickness". Braz J Med Biol Res. 39 (2): 277–81. PMID 16470316.

External links

Template:Pharma-stub